Paulo Fontoura

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Intellectual Disability

Autism Spectrum Disorder

Top Venues

Journal of neurology

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Federico Bolognani, Marta Del Valle Rubido, Lisa Squassante, Christoph Wandel, Michael Derks, Lorraine Murtagh, Jeffrey Sevigny, Omar Khwaja, Daniel Umbricht, Paulo Fontoura
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science translational medicine 11 (491) (2019)